Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Abraxane, and Bevacizumab in Advanced NSCLC
NCT00642759Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2008
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Primary endpoint: Progression-Free Survival Rate at 6 months. Started Apr 2008; status: completed.
02
Drugs
paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00642759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00642759.